OrbusNeich Medical's P/E ratio aligns with other firms despite limited growth expectations, hinting at potential investor oversight. The company's future prospects based on the P/E ratio alone are not promising, as the predicted future earnings are unlikely to support a more positive sentiment for long.
Despite increased capital investment, the company's ROCE has remained flat, suggesting a lack of high return investments. A 61% stock price drop over the last year indicates investor skepticism about growth prospects.
HopelessChi
:
heavily punished since 2020 clampdown. this was the cause of the powerful clan and the impact is now more than 3 years. this market entirely had lost investors
ORBUSNEICH Stock Forum
Active Heavyweights:
$MEITUAN-W (03690.HK)$ closed at $90.45, down 12.2%
$BABA-W (09988.HK)$ closed at $72.7, down 2.2%
$HKEX (00388.HK)$ closed at $279.6, do...
No comment yet